Will Rivaroxaban Be Cost-Effective for Prevention. of Venous Thromboembolism after Total Hip Replacement in US Patients?.

被引：0
|
作者：
Kwong, Louis [1 ]
Diamantopoulos, Alexander [2 ]
Forster, Fiona [2 ]
Sengupta, Nishan
Lees, Michael [3 ]
机构：
[1] Harbor UCLA Med Ctr, Torrance, CA 90509 USA
[2] IMS Hlth, London, England
[3] Bayer PLC, Uxbridge, Middx, England
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：467 / 467
页数：1
相关论文
共 50 条
  • [31] Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement A randomised, controlled trial
    Verhamme, Peter
    Gunn, Sophie
    Sonesson, Elisabeth
    Peerlinck, Kathelijne
    Vanassche, Thomas
    Vandenbriele, Christophe
    Ageno, Walter
    Glazer, Steven
    Prins, Martin
    Buller, Harry
    Tangelder, Marco
    THROMBOSIS AND HAEMOSTASIS, 2013, 109 (06) : 1091 - 1098
  • [32] Strategies for cost-effective prevention and treatment of venous thromboembolism - Introduction
    Nutescu, EA
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (23) : S3 - S4
  • [33] Fondaparinux is cost-effective compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing surgery for hip replacement.
    Sullivan, SD
    Kahn, SR
    Muntz, JE
    PHARMACOTHERAPY, 2003, 23 (10): : 1355 - 1355
  • [34] Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain
    Monreal, Manuel
    Folkerts, Kerstin
    Diamantopoulos, Alex
    Imberti, Davide
    Brosa, Max
    THROMBOSIS AND HAEMOSTASIS, 2013, 110 (05) : 987 - 994
  • [35] Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
    Mueck, Wolfgang
    Borris, Lars C.
    Dahl, Ola E.
    Haas, Sylvia
    Huisman, MennoV.
    Kakkar, Ajay K.
    Kalebo, Peter
    Muelhofer, Eva
    Misselwitz, Frank
    Eriksson, Bengt I.
    THROMBOSIS AND HAEMOSTASIS, 2008, 100 (03) : 453 - 461
  • [36] COST ASSESSMENT OF DRUGS FOR VENOUS THROMBOEMBOLISM PREVENTION AFTER HIP OR KNEE REPLACEMENT IN MEXICAN POPULATION
    Contreras, I
    Torres-Gonzalez, R.
    Ocegueda-Sosa, M. A.
    Hernandez-Cuevas, V
    Mendoza-Lemus, O. F.
    Vilchez-Cavazos, F.
    VALUE IN HEALTH, 2012, 15 (07) : A369 - A369
  • [37] COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP OR TOTAL KNEE REPLACEMENT SURGERY
    Wolowacz, S.
    Roskell, N.
    Maciver, F.
    Beard, S.
    Robinson, P.
    Plumb, J.
    VALUE IN HEALTH, 2008, 11 (06) : A404 - A404
  • [38] Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgery
    Baser, Onur
    Supina, Dylan
    Sengupta, Nishan
    Wang, Li
    Kwong, Louis
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (02) : 423 - 429
  • [39] PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP AND KNEE ARTHROPLASTY
    LIEBERMAN, JR
    GEERTS, WH
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1994, 76A (08): : 1239 - 1250
  • [40] PREVENTION OF THROMBOEMBOLISM AFTER TOTAL HIP-REPLACEMENT SURGERY
    GRIFFIN, JW
    PHYSICAL THERAPY, 1988, 68 (05): : 822 - 822
12345